Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

March 6, 2013 updated by: Teva GTC

MultiCTR Randomized Double-Blind Double-Dummy Study to Evaluate Clinical Efficacy/Safety of DR 6MP for Targeted Ileal Delivery vs Purinethol in Patients w/Moderately Active Crohn's Disease

The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12 weeks of oral administration of a delayed release, locally delivered 6MP (mercaptopurine) drug (80 mg), as compared to standard Purinethol (at a dose of 1-1.5 mg/kg/body weight), in alleviating the clinical, immunological and mucosal signs and symptoms of moderately active Crohn's Disease

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Crohn's Disease (CD) therapy is aimed at reducing inflammation via induction of remission after a flare-up and maintenance of the remission for as long as possible. Therapies commonly used for inducing remission are steroids and anti-TNF-a. Standard 6MP, on the other hand, has a slow onset of action and requires several months of administration before its therapeutic effects become apparent. Therefore, 6MP is typically used as maintenance therapy, rather than for remission. Furthermore, serious AE's associated wtih 6MP include leucopenia, hepatoxicity, pancreatitis and bone marrow suppression, requiring lowering of dose or treatment discontinuation.

The Teva DR-6MP project was designed to evaluate a new oral 6MP formulation that would address these limitations. The slow action of standard 6MP, precluding its use as a treatment for induction of remission, would be offset by a faster-disintegrating, more soluble formulation with an enteric coating for targeted ileal delivery. This new formulation designed to open at the terminal ileum, the most commonly affected area of CD bowel involvement, could deliver higher effective local concentrations of drug to the site most affected by CD, stimulating an effective local immunological response, resulting in a cascade of widespread immunological activity, evoking an induction of remission. The safety of standard 6MP would be improved upon by the fact that negligible levels of the DR-6MP formulation have been observed in the plasma, obviating the toxicities associated with systemic 6MP. Moreover, since the DR-6MP dose is fixed and not subject to patient weight, nor potentially, side-effects, the dose adjustments required for up-titration to optimal dose, or down-titration due to toxicity, could be avoided.

Previous small, pilot proof-of-concept clinical efficacy and pharmacokinetic studies of the DR-6MP formulation demonstrated the potential for induction of remission, mucosal healing, systemic immunological improvement and lower systemic side-effects.

The current study is designed to repeat the earlier studies under larger, more rigorous conditions in a randomized, double-blind fashion at multiple sites to ascertain if the initial encouraging results could be repeated. Moreover, a higher dose of 6MP (80 mg) will be tested to ascertain if presumably higher local concentrations at the disease site can evince a more robust clinical effect.

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
      • Afula, Israel
        • Ha'Emek Medical Center
      • Haifa, Israel
        • Rambam Medical Center
      • Haifa, Israel
        • Bnai Zion Hospital
      • Jerusalem, Israel
        • Hadassah Medical Center
      • Jerusalem, Israel
        • Shaarei Tzedek Medical Center
      • Kfar Saba, Israel
        • Meir Medical Center
      • Nazareth, Israel
        • Holy Family Hospital
      • Rehovot, Israel
        • Kaplan Medical Center
      • Tel Aviv, Israel
        • Tel Aviv Sourasky Medical Center
      • Tel Hashomer, Israel
        • Sheba Medical Center
      • Zerifin, Israel
        • Assaf Harofeh

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 73 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Male or (non-pregnant) female, 18-75 years (incl) at screen.
  2. Diagnosed w/CD, appropriately documented/supported by endoscopy or radiology.
  3. W/ moderately active CD, w/ screen CDAI score 220-450 (inclusive)

  4. Screen lab tests:

    • HGB >/= 8.5 g/dL,
    • Platelets >/= 100,000/ mm³
    • WBC >/= 3500 mm³
    • Serum albumin > 2.5 g/dL
    • ALT, AST, ALK Phos, GGTP,. total and direct bilirubin < 2xULN
  5. Subjects may be on stable (for at least 2 wks prior screen) 5-ASA, chronic antibiotics or low-dose oral steroids (prednisolone-up to 15 mg daily; budesonide-up to 6 mg daily) and remain on the drug at that dose throughout the study
  6. Willing and able to provide written ICF.

Exclusion Criteria:

  1. W/ ulcerative colitis or w/ diagnosis of indeterminate colitis.
  2. W/ previous bowel resection due to CD resulting in clinically significant Short Bowel Syndrome.
  3. W/ fistulizing CD w/ clinic or radiologic evidence of abscess.
  4. W/ clinically significant GI obstructive symptoms or x-ray evidence of fibrosed bowel.
  5. W/ screen stool culture + for enteric pathogens (Salmonella, Shigella, Campylobacter) or Clostridium difficile toxin assay.
  6. W/ hx of persistent intestinal obstruction, bowel perforation, uncontrolled GI bleed,abdominal abscess,infection or toxic megacolon.
  7. W/ hx of GI tract malignancy or IBD-associated malignant intestinal changes.
  8. W/ surgery/major procedure in 4 weeks prior to 1st study dose.
  9. Receiving elemental diet or parenteral nutrition.
  10. W/ current signs/symptoms of clinically significant/unstable med/surg condition that precludes safe/complete study participation, determined by med history, PE, ECG, lab tests or imaging. Such conditions may include severe, progressive or uncontrolled renal, metabolic, hepatic, hematologic, endocrine, pulmonary, cardiovascular, psychiatric, neurologic, cerebral or autoimmune disease.
  11. W/ serious infections, such as hepatitis, pneumonia, pyelonephritis w/in 12 weeks prior to 1st study dose. Less serious infections such as acute UR tract infections or uncomplicated UT infection not considered exclusions - at discretion of PI.
  12. W/ currently known malignancy/pre-malignant lesions/hx of malignancy w/in past 5 years, excl basal cell carcinoma.
  13. W/ hx of coagulopathy.
  14. W/ porphyria as it may interfere w/ assessment of CD abdominal pain.
  15. W/ hx of previous thiopurine failure resulting in serious AE (ex: severe pancreatitis, leucopenia, hepatoxicity or bone marrow suppression) so as to preclude addtl tx w/ 6MP at any dose
  16. Taking w/in 6 months prior to 1st study dose (+during study) Active vaccinations (live attenuated bacterial/viral pathogens)

  17. Taking w/in 6 weeks prior to 1st study dose (+ during study):

    • Anti-TNFα (infliximab, etanercept, adalimumab)
    • Anti-integrin (natalizumab)
    • Anti-neoplastics, incl methotrexate, daunorubicin hydrochloride

  18. Taking w/in 4 weeks prior to 1st study dose (+ during study):

    • Immunosuppressants such as AZA, 6-MP (i.e., other than 6MP drug assigned during study), cyclosporine, tacrolimus, mycophenolate mofetil or thalidomide.
    • Antibiotics or oral/IV corticosteroids (other than oral prednisolone allowed during study as rescue therapy as per protocol).
    • Tx w/ drugs known to induce/inhibit endogenous hepatic drug metabolism such as barbiturates, phenothiazines, cimetidine, carbamazepine etc.
    • Anti-coagulant therapy such as: heparin, warfarin, acenocoumarol.
    • Medications that induce blood dyscrasias or w/ potential for immune dysfunction, bone marrow depression and/or symptoms of CD (diarrhea, abdominal pain).
    • Vaccinations involving inactivated forms of pathogens or purified antigenic proteins (Note: passive immunization involving antibody inoculations permitted at any time)

  19. Tx w/in 2 wks prior to 1st study dose (+ during study) IV or oral steroids (prednisolone or budesonide) Antibiotics

    Note: 2 impt exceptions (a) Subjects oral steroid or antibiotic dependent with active CD (CDAI 220-450)in spite of these txs, may remain on tx provided on stable (>=2wks at screen)dose and remain at that dose throughout study (b) Subjects who require steroid-rescue during study

  20. Taking w/in 7 days prior to 1st study dose (+ during study):

    • Anticholinergic or other drugs known to affect GI motility.
    • Allopurinol
    • Proton pump inhibitors or other drugs affecting gastric acidity
  21. W/body weight below 42.5 kg.
  22. Pregnant/nursing at screen, or intend to be during study.
  23. Women of childbearing potential not practicing acceptable method of birth control [acceptable methods: surgical sterilization, IUD, contraceptive (oral, patch, or long-acting injectable), partner's vasectomy, double-protection method (condom or diaphragm w/ spermicide) or abstinence].
  24. W/ current/hx of drug and/or alcohol abuse.
  25. Largely or wholly bed-ridden and w/ little capacity for self-care.
  26. W/ known allergy or hypersensitivity to 6-MP or any inactive component of study drug (ex: lactose intolerant).
  27. Participated in other clinical trial using investigational drugs w/in 12 weeks prior to 1st study dose.
  28. W/ planned elective surgery or hospitalization during study (that may interfere w/ study compliance/outcome).
  29. W/inability to communicate well w/investigators/staff (i.e., language problem, poor mental development or impaired cerebral function).
  30. Unavailable for trial duration, unable to comply w/schedule, likely to be noncompliant, or felt unsuitable by PI for any other reason.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Delayed Release 6MP

6 Mercaptopurine delayed release oral tablet for targeted ileal delivery, to be administered once nightly before bedtime, for 12 weeks.

The dose is 2 x 40 mg DR-6MP (total dose, 80 mg DR-6MP).
Drug: Delayed Release 6 mercaptopurine

Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.

Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets.

Other Names:
  • Delayed Release 6 MP tablet (80 mg)
Active Comparator: Purinethol
6 Mercaptopurine Tablet (50 mg) administered orally, at doses of 1-1.5 mg/kg body weight, daily for 12 weeks. Individual patient doses range from 50 mg to 150 mg, including 75, 100 and 125 mg daily, as per patient weight at baseline, and then are up-titrated to clinical efficacy at two week intervals, as needed. Doses may be down-titrated as well if occurrences of AE's warrant dose reduction.
Drug: 6 Mercaptopurine
Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
Other Names:
  • Purinethol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of subjects with clinical response at study end
Time Frame: 12 weeks
Clinical response is defined as a reduction in CDAI score (Crohn's Disease Activity Index) by 100 points from baseline, or remission (CDAI score <150),even if it is achieved with reduction of CDAI score of less than 100 points from baseline
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to clinical response
Time Frame: Week 2, 4, 6, 8 or 12
Although the primary outcome is to assess the proportion of patients with clinical response at Week 12, we are also interested to see how early during treatment (i.e., between weeks 2 and 12), was this clinical response actually achieved for each treatment group, and if it was maintained until the end of the study (week 12)
Week 2, 4, 6, 8 or 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Teva GTC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2010

Primary Completion (Actual)

December 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

March 25, 2010

First Submitted That Met QC Criteria

March 25, 2010

First Posted (Estimate)

March 29, 2010

Study Record Updates

Last Update Posted (Estimate)

March 7, 2013

Last Update Submitted That Met QC Criteria

March 6, 2013

Last Verified

March 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Protocol C2/13/DR-6MP-02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Crohn's Disease

Clinical Trials on Delayed Release 6 mercaptopurine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe